Last reviewed · How we verify

Tramadol IV (Tradonal® IV)

University Hospital, Ghent · FDA-approved active Small molecule

Tramadol is an opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.

Tramadol is an opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief. Used for Moderate to severe acute pain (postoperative pain, trauma-related pain), Severe pain requiring parenteral opioid therapy.

At a glance

Generic nameTramadol IV (Tradonal® IV)
SponsorUniversity Hospital, Ghent
Drug classOpioid analgesic with monoamine reuptake inhibition
TargetMu opioid receptor; norepinephrine transporter; serotonin transporter
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Tramadol works through dual mechanisms: it acts as a weak mu opioid receptor agonist and simultaneously inhibits the reuptake of norepinephrine and serotonin in the central nervous system. This combination of opioid and monoamine reuptake inhibition produces analgesic effects for moderate pain. The IV formulation allows for rapid onset and is typically used for acute postoperative or severe pain management in hospital settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results